Multifactorial Analysis of Affinity-Mass Spectrometry Data from Serum Protein Samples: A Strategy to Distinguish Patients with Preeclampsia from Matching Control Individuals  by Pecks, Ulrich et al.
FOCUS: AFFINITY MASS SPECTROMETRY
Multifactorial Analysis of Affinity-Mass
Spectrometry Data from Serum Protein
Samples: A Strategy to Distinguish Patients
with Preeclampsia from Matching Control
Individuals
Ulrich Pecks,a* Franka Seidenspinner,a,b* Claudia Röwer,b
Toralf Reimer,c Werner Rath,a and Michael O. Glockerb
a Department of Obstetrics and Gynecology, Medical Faculty, RWTH Aachen, Aachen, Germany
b Proteome Center Rostock, Medical Faculty and Natural Science Faculty, University of Rostock, Rostock, Germany
c Department of Obstetrics and Gynecology, Medical Faculty, University of Rostock, Clinic Suedstadt, Rostock,
Germany
A multifactorial differential analysis of serum proteins using mass spectrometry distinguished
samples from pregnant women with severe early-onset preeclampsia (n  11) from those of
control individuals with uneventful pregnancies (n 13). Serum proteins were fractionated by
either their affinities to reversed-phase material coated magnetic beads or by fractionated
precipitation. The on-average most abundant ion signals were observed at m/z 9390, 9103, and
8886. The best differentiating ion signals between the two sample groups were found at m/z
13,715, 13,834, and 13,891. The normalized intensities of these ion signals were on-average
lower in the preeclampsia group than in the control group. The six ion signal intensities
enabled sorting of the individual spectra with high accuracy. Sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) analysis showed that a protein band migrat-
ing just above the 14 kDa marker band contained transthyretin (P02766; Mr (avg.): 13,761).
Densitometric analysis of the transthyretin bands showed lower intensities in the preeclampsia
samples with respect to those of the controls. Nephelometric analysis of the serum samples
determined the mean concentration of transthyretin in the preeclampsia group were lower
(0.16 mg/mL; range: 0.13 to 0.20; SD: 0.03) than that in the control group (0.19 mg/mL; range:
0.14 to 0.22; SD: 0.02), substantiating the role of transthyretin concentration differences in the
comparison of the two groups. Altogether, our findings support the theory of preeclampsia
being a heterogeneous disorder that might be sub-classified by a defined proteome signature
in maternal blood using multifactorial analysis of affinity-fractionated serum samples. (J Am
Soc Mass Spectrom 2010, 21, 1699–1711) © 2010 American Society for Mass SpectrometryPreeclampsia is a pregnancy-related hypertensivedisorder. It affects  3% to 5% of pregnantwomen, and is a major cause of maternal and
neonatal morbidity and mortality. Because the only
definitive treatment available thus far is delivery, pre-
eclampsia is one of the leading causes of a mandated
prematurity [1]. Preeclampsia is associated with pro-
teinuria, and its symptoms usually manifest after the
20th week of gestation. It is considered a multisystemic
disorder associated with generalized endothelial dys-
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doi:10.1016/j.jasms.2009.12.013function, thus affecting many organs, including the
kidney, liver, and the nervous system [2]. Its major
complications are eclampsia and HELLP syndrome,
both of which are potential life-threatening events.
Eclampsia is characterized by grand mal-like seizures,
whereas HELLP syndrome manifests itself with hemo-
lysis, elevated liver enzymes, and low platelet counts
[3]. Furthermore, the underlying condition has the
potential to affect the fetus, as about 25% of babies born
to women with preeclampsia are small for gestational
age (SGA).
The pathogenesis of preeclampsia still remains un-
clear. Current hypothesis states that placental ischemia
is due to a shallow placental trophoblast invasion into
the maternal decidua and a lack of spiral artery remod-
eling [4, 5]. As a response, the ischemic placenta re-
leases a number of cell fragments and proteins into the
maternal circulation. Hence, trophoblast cells and cell-
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pregnancies complicated by preeclampsia [6, 7]. Likely the
development of preeclampsia involves several differ-
ent pathophysiological mechanisms, as evidenced by
the diversity of proteins that have been studied to
date.
The use of a growing number of biomarkers has
been suggested for the detection and prediction of
preeclampsia. Recently, serum concentrations of pro-
and anti-angiogenic factors, such as placental growth
factor (PlGF), soluble vascular endothelial growth fac-
tor receptor-1 (sVEGFR-1 or sFlt-1), and soluble endog-
lin were found to be altered in maternal blood, even
weeks before the onset of symptoms [8, 9]. Other
molecules that appear promising as early markers in-
clude activin A, inhibin A, pentraxin 3 (PTX3), pregnancy-
associated plasma protein-A (PAPP-A), and placental
protein 13 (PP13) [10–15]. However, a large systematic
review in 2004 concluded that no single test currently
available to predict preeclampsia was sufficiently reli-
able for clinical use [16]. Consequently, up to now none
of the discussed markers has found widespread appli-
cation in clinical routine.
One of the approaches to study polygenic diseases
that generated considerable interest due to its clinical
potential is proteomic pattern diagnostics. Matrix-
assisted laser desorption/ionization-time of flight mass
spectrometry (MALDI-TOF MS) is an automated tech-
nique that can detect hundreds of peptide and/or
protein ion signals from clinically obtained body fluids
in one measurement with good reproducibility and
robustness. Hence, MALDI-TOF MS has enabled the
multiparametric analysis of the reservoir of proteins
derived from high-abundance endogenous circulating
molecules from pregnant women [3, 17]. As a conse-
quence, mass spectrometric measurements of the en-
tire set of protein abundances in biological fluids
(proteome signatures) allow the representation of a
particular pathology, and the resulting signature is in
the best case unique to the disease. In everyday
application, protein signatures are validated against
defined patient cohorts to show their specificities
within a particular set of samples. One advantage of
proteomics is that this approach does not require
prior knowledge of the pathophysiological mecha-
nisms underlying the condition of interest or even the
existence of any single specific protein, as long as the
signature of recorded signals remains differential
[18].
In our study presented here, we aimed as a first step
to assess MALDI-TOF mass spectrometry-based serum
protein analysis as a means to detect preeclampsia
patients by analyzing samples from pregnant women
and to investigate the possibility of the method to
reliably differentiate patient samples from those of
control individuals, a prerequisite for potential clinical
use.Materials and Methods
Selection of Patients/Donors, Blood Sample
Collection, and Storage of Serum Aliquots
The study was approved by the Ethics Committee of the
RWTH Aachen (EK 138/06). Written informed consent
was obtained from all participating women. We ana-
lyzed serum samples from 24 pregnant Caucasian
women attending the Department of Obstetrics and
Gynecology, University Hospital of the RWTH Aachen
between October 2006 and December 2008. Of those, 13
healthy women had an uneventful pregnancy and 11
pregnancies were complicated by preeclampsia.
Preeclampsia was defined by the following criteria:
(1) a blood pressure in a previously normotensive
woman higher than 140 mm Hg systolic or 90 mm Hg
diastolic on two or more occasions or on automated
24-h blood pressure monitoring, (2) a urinary protein
content greater than 300 mg/L in a 24-h collection, or
(3) at least a 2 reading in urine dip stick on a random
sample. The definition is in accordance to the criteria of
the International Society for the Study of Hypertension
in Pregnancy and the Consensus Report of the US
National High Blood Pressure Education Program [19,
20]. Furthermore, to obtain a homogeneous study group,
only patients with early onset preeclampsia 34  0
weeks and with appropriate fetal growth were included
as already suggested by others [21, 22]. Gestational age
was established on the basis of the last menstrual period
and confirmed by ultrasonic examination between 10th
and 14th week of gestation. Neonatal birth weight
centile was determined according to the population-
based newborn weight charts [23]. Patients with clinical
or biochemical signs of infection, diabetes, gestational
diabetes, or HELLP syndrome at time of sampling were
excluded. None of the samples obtained were taken
during labor.
Important clinical and laboratory parameters by
which the patients and control individuals were char-
acterized were blood pressure, urinary protein content,
and week of gestation at time point of sample collection
(Table 1). Blood samples (9 mL) were taken antenatally
from right or left cubital vein using monovette syringes
(Serum Z/9 mL; Monovette, Sarstedt, Germany). After
incubation at room temperature for 15–30 min, samples
were subjected to sedimentation of blood cells by cen-
trifugation at 2000 g at room temperature for 15 min.
Serum was aspirated and divided into aliquots (100 L
each), which were stored at 80 °C. Altogether, time
between blood sample collection and storage of serum
aliquots averaged below 1 h.
Protein Extract Preparation from Serum Samples
using the Profiling Kit 100 MB-HIC8
Serum samples were processed according to manufac-
turer’s instructions using the Profiling Kit 100 MB-HIC8
(Bruker Daltonik, Bremen, Germany). From each thawed
e pop
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HIC8 “binding buffer” and 5 L of MB-HIC8 bead
slurry for 1 min. After washing twice (100 L of “wash
buffer,” each), proteins were eluted with 10 L of
“elution buffer,” consisting of a 50% ACN solution.
Protein Extract Preparation from Serum Samples
by Fractionated Precipitation
Serum samples were thawed and fractionated precipi-
tation was performed according to described proce-
dures [24]. Briefly, to 10 L of serum sample, 7 L of
chilled ethanol (20 °C; 40% ethanol, vol/vol) was
added and kept on ice for 10 min. The pellet (fraction I)
was collected by centrifugation with 13,000 g at 4 °C.
Proteins dissolved in the ice-cold supernatant (17 L)
were precipitated by addition of 3 l of chilled ethanol
(50% ethanol, vol/vol). After 10 min incubation at
20 °C, precipitated proteins (fraction II) were collected
by centrifugation as described above.
MALDI-TOF MS Profiling of Serum Proteins
After MB-HIC8 extraction, protein solutions (0.5 L
Table 1. Demographic data and clinical parameters of patients
Patient/
individual
Agea
[a]
BMI before
pregnancy
[kg/m2]
Gestational
agea [wd]
Median blood
pressurea,b
[mm Hg]
1 23 29 316 148/101
2 26 27 276 160/97
3 29 22 324 155/95
4 30 37 315 143/84
5 24 32 320 153/83
6 38 19 304 162/97
7 32 26 292 142/84
8 26 21 324 145/88
9 46 23 254 183/105
10 33 23 236 144/93
11 34 23 320 176/113
12 31 37 304 122/74
13 28 40 336 128/74
14 21 19 315 111/65
15 33 28 303 111/65
16 38 21 280 98/52
17 28 21 240 95/60
18 30 33 283 111/56
19 26 20 282 130/70
20 39 22 280 120/70
21 40 26 322 120/75
22 28 30 313 134/72
23 27 23 305 120/46
24 35 19 300 103/60
aAt beginning of hospitalization (time point of sample collection).
bSystolic/diastolic blood pressure; preeclampsia is defined as 140 m
normotensive prior to the 20th week of gestation.
cImmunoturbidimetric assay (Tina-quant albumin; Roche Diagnostics,
300 mg/L.
dDip stick assay; significant proteinuria is present with readings of mo
eGestational weeks at time point of delivery.
fStandard deviations to the mean birth weight centiles according to theach) were spotted directly onto a stainless steel MTP384 target plate (Bruker Daltonik) before matrix solu-
tion was added (see below). Alternatively, after frac-
tionated precipitation protein pellets were re-dissolved
in 10 L of a solution consisting of 50% ACN/0.3%
TFA/5 mM n-OGP and agitated for 30 min. Insoluble
remainders were disposed by centrifugation before
further use of the solubilized sample; 0.5 L from the
protein solution were deposited on a stainless steel
MTP 384 target plate. In either case 1.5 L of saturated
ferulic acid solution (dissolved in ACN/0.1% aqueous
TFA (33/67, vol/vol)) was added as matrix to each
sample spot. For each sample, spots were prepared in
duplicate for recording first and second measurements,
M1 andM2, respectively. The entire profiling procedure
was repeated and all samples were examined once
again in duplicate, yielding in measurements M3 and
M4. One sample measurement series (M5) was recorded
after fractionated precipitation. Protein mixtures were
analyzed with a Reflex III MALDI TOF mass spectrom-
eter (Bruker Daltonik) equipped with the SCOUT
source and delayed extraction and operated in linear
positive ion mode using an acceleration voltage of 20
kV [25]. Spectra were recorded in a mass range from 4 to
25 kDa and 20 to 250 kDa, respectively, accumulating 900
ed in the study
oteinuriaa,c,d
[mg/l]
Gestational age
at deliverye
[wd]
Birth weight
[g]
Birth weight
centilef [SD]
6760 320 1325 1.52
652 283 830 1.43
3d 325 1345 1.47
451 316 1395 0.85
9140 323 1460 1.18
3382 311 1730 0.10
555 322 1465 1.17
2293 331 1690 1.22
2342 262 760 1.00
384 255 680 1.02
2684 322 1380 1.38
180 385 2800 1.33
96 390 3850 0.86
49 390 3700 0.50
79 386 3710 0.85
1d 380 3340 0.04
0d 410 3995 0.81
0d 361 2630 0.80
0d 376 2915 0.65
0d 373 2860 0.78
0d 382 2590 1.83
0d 384 3335 0.05
0d 414 3485 0.34
0d 386 3120 0.56
systolic or 90 mm Hg diastolic blood pressure in women who were
heim, Germany); proteinuria is defined as urinary protein excretion
n 1.
ulation based newborn weight charts.includ
Pr
m Hg
Mann
re thashots per spectrum. Spectra were externally calibrated
1702 PECKS ET AL. J Am Soc Mass Spectrom 2010, 21, 1699–1711using a commercially available Protein Calibration Stan-
dard (Bruker Daltonik).
Bioinformatic Analysis of Linear MALDI-TOF MS
Ion Signals
The ClinProTools 2.2 software (Bruker Daltonik) was
used to analyze the spectra from the patients and
controls, respectively. Each dataset was generated in
duplicate, i.e., two independent measurements were
recorded from each sample. The first sample work-up
with the beads resulted in datasets M1 and M2, and the
second work-up in datasets M3 and M4, respectively.
The work-up with fractionated precipitation yielded in
dataset M5. Analysis for each dataset was carried out
independently from each other. Settings were specified
and remained unchanged for all measurement analyses
for (1) peak picking, which happened on the total
average spectrum of the particular class, (2) for signal to
noise threshold, value was set to 5.00, and (3) the value
for the relative threshold base peak was set to 0.00.
Smoothing of spectra was performed applying the
Savitzky-Golay algorithm, width 2.0 m/z for three cy-
cles. Spectra were recalibrated automatically, taking
only those masses into account that occurred in at least
30% of the spectra. The maximal mass tolerance be-
tween reference mass and peak mass was set to 1500
ppm. Hence, those spectra were excluded from analysis
which either could not be recalibrated due to larger
mass differences or which contained too few ion signals
for calibration. Baseline subtraction was performed in
the “Top Hat Baseline mode” and null spectra exclusion
was enabled. All ion intensities in the spectra were
normalized to their own total ion count (TIC), which
was determined as the sum of all intensities of the
spectrum. Subsequently, all intensities of this spectrum
were divided by the obtained TIC value. Statistical
significance of the mass spectra was analyzed with a
Wilcoxon rank-sum test [26] expanded by the use of a
Kruskal-Wallis test [27] and a Student’s t-test for two
populations [28, 29] expanded by the use of an ANOVA
test on significance levels of 0.05. Probability distribu-
tions were analyzed with an Anderson-Darling test [30].
The Wilcoxon rank-sum test is a nonparametric signif-
icance test for assessing two samples from a single
population, whereas the Kruskal-Wallis test is applied
instead of the Wilcoxon rank-sum test when more than
two populations are involved. In our studies, the statis-
tical analyses of the mass spectra were performed with a
Wilcoxon rank-sum test. The two-sided two-sample
Student’s t-test that was applied in our studies is
used for comparing two populations and their data
differences. The ANOVA test can be applied instead of
the Student’s t-test when more than two populations
are involved. The Wilcoxon rank-sum test, in contrast to
the Student’s t-test, does not assume normally distrib-
uted data. Statistical significance between ion signal
quotients among the two groups was tested with atwo-sided Student’s t-test for two populations on a
significance level of 0.05. Graphical representations as
box-and-whisker plots [31] were realized using the
Origin software (version 6.1G; OriginLab Corporation,
Northampton, MA, USA).
SDS Polyacrylamide Electrophoresis and
Gel Imaging
Proteins from the pellet of fraction II were re-dissolved
in 300 L of SDS sample buffer (2% SDS, 65 mM
Tris/HCl (pH 6.8), 5% glycerol, and bromophenol blue)
at room temperature. SDS PAGE was carried out as
described [32]. In short, SDS polyacrylamide gels, 10% T
for the analysis of high mass proteins and 12% T for
analyzing proteins in the low mass range (Invitrogen,
Carlsbad, CA, USA), were run for 1 h at 200 V in a
Novex Minicell Vertical Electrophoresis System (In-
vitrogen) applying the Laemmli continuous buffer sys-
tem [33]. Gels were fixed and then stained with colloi-
dal Coomassie brilliant blue G-250 [34, 35]. The broad
range marker kit (New England BioLabs Inc., Frankfurt
am Main, Germany) was used as apparent molecular
mass calibration. Stained gels were scanned with the
Umax Mirage II Scanner (Umax Data Systems, Willich,
Germany) and images were stored as 16 bit tif files. For
densitometric image analysis the software package
Phoretix 2D Advanced, version 6.01 (Nonlinear Dy-
namics Ltd., Newcastle upon Tyne, UK) was used.
Mass Spectrometric Peptide Mass Fingerprinting
Protein bands of interest were excised manually and gel
plugs were subjected to in-gel digestion with trypsin
(Promega, Mannheim, Germany) [3]. Sample prepara-
tion of peptide mixtures was performed on an Anchor-
Chip 600/384 target plate [32] using CHCA as matrix.
Peptide mixtures were analyzed with a Reflex III
MALDI TOF mass spectrometer (Bruker Daltonik)
equipped with the SCOUT source and delayed extrac-
tion and operated in positive ion mode using an accel-
eration voltage of 20 kV [25]. Spectra were externally
calibrated using a commercially available Peptide Cal-
ibration Standard (Bruker Daltonik) as well as inter-
nally recalibrated using the following peptide ion sig-
nals derived from trypsin autoproteolysis: [M  H]
842.51, [M  H] 1045.54, [M  H] 2211.10, [M  H]
2807.39. Mass spectra were further processed and ana-
lyzed with the FlexAnalysis 2.4 and BioTools 3.0 soft-
wares (both Bruker Daltonik). Database searches were
performed against an in-house SWALL database that
consists of Swiss-Prot release 56.8 and TrEMBL release
39.8 using Mascot version 2.2.03 software (Matrix Sci-
ence, London, UK) with the following search parame-
ters: taxonomy: human, peptide tolerance: 60 ppm,
fixed modifications: carbamidomethylation of cys-
teines, variable modifications: oxidation of methionines,
1 missed cleavage site.
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Peptide mixtures from in-gel digests (1 L) were mixed
with matrix solution (1 L) on an AnchorChip 600/384
target plate. The matrix solution contained 5 mg DHB
which were dissolved in 1 mL of solvent that consisted
of 50% ACN and 50% of a 0.1% TFA solution (vol/vol).
MS/MS spectra were recorded on an Axima MALDI
QIT TOF mass spectrometer (Shimadzu Biotech,
Manchester, UK) utilizing a nitrogen pulsed laser (337 nm,
3–5 ns pulse length) and employing a three-dimensional
ion trap supplied by helium (pulsed flow gas) for colli-
sional cooling and argon (collisional gas) for collisionally
induced dissociation (CID) [36, 37]. Precursor ions were
excited with off-resonance sinusoidal waveforms whereas
at the same time argon was allowed to enter the trap.
For fragmentation, the width of the precursor ion
selection window was dependent on the mass of the
precursor ion and varied between 2 and 10 Da. Spectra
were externally calibrated with a manually mixed pep-
tide standard consisting of bradykinin (1–7), [M  H]
757.39; angiotensin II, [M  H] 1046.53; angiotensin I,
[M  H] 1296.68; bombesin, [M  H] 1619.81; N-
acetyl renin substrate, [M  H] 1800.93; ACTH (1-7),
[M  H] 2093.08; ACTH (18-39), [M  H] 2465.19;
somatostatin, [M  H] 3147.46; insulin (oxidized beta
chain), [M  H] 3494.64; as well as internally recali-
brated using known ion signals of the MS/MS spec-
trum. Further processing and analysis of the MS/MS
spectra was performed with the Launchpad software,
version 2.8.4 (Shimadzu Biotech, Manchester, UK).
Nephelometric Determination of Transthyretin
Levels in Serum
Concentrations of transthyretin in serum samples were
determined nephelometrically using the Dade Behring
assay system at the automated Dade Behring Nephe-
lometer II (BN II; Dade Behring, Marburg, Germany)
according to the manufacturer’s protocol. Reference
values for transthyretin in serum are 0.2–0.4 mg/mL
according to the method sheet; 250 L of freshly thawed
serum was used for each measurement.
Statistical Power Analysis
To evaluate the minimal required sample size that is
needed to discriminate the group with preeclampsia
from the control group on the basis of the obtained data,
we carried out a power analysis [38, 39] using the
MedCalc statistical software. We chose a type I error ()
of 0.05 and a type II error () of 0.20 in a comparison of
two means which is typically suggested for this type of
analysis. Thus, we achieved a minimal required sample
size with a power (1-) of 80% and a level of signifi-
cance below 0.05.Results
Selection of Patients and Sample Preparations
Patient samples were selected such as to attain a ho-
mogenous study group by focusing on the more severe
early-onset form (34 gestational week) of preeclamp-
sia. The late-onset form is more evanescent and of lesser
clinical importance [40]. Furthermore, we excluded
women with concomitant intrauterine growth restric-
tion (as defined by a decrease in growth velocity) or
small-for-gestational-age neonates (SGA, as defined by
a birth weight centile below –2 SD of the mean).
Twenty-four pregnant women at median age of 30 y
(range: 21–45 y) were included in the study. The patient
group comprised 11 pregnant women with early onset
preeclampsia (PE). The control group consisted of 13
healthy pregnant women with uneventful pregnancies
(CN) matching with the PE group in both maternal and
gestational age (Table 1). All women in the PE group
required iatrogenic preterm delivery before 34 com-
pleted weeks of gestation because of deteriorating ma-
ternal condition and/or signs of fetal distress. Hence,
despite the set exclusion criteria, birth weight centiles
were significantly reduced in our study group com-
pared with the healthy control group.
From all individuals, blood samples were taken and
serum proteins were isolated with standardized proce-
dures. Subsequently, fractionation of serum proteins
was conducted by either applying a reversed-phase
coated bead system (ClinProt) or by conducting frac-
tionated precipitation. Both approaches proved equally
suitable for fractionation of serum proteins and yielded
in samples that were applicable for MALDI-MS profil-
ing without further work-up (see below). An overview
mass spectrum in the “high mass” range showed pro-
tein ion signals between m/z 25,000 and 200,000 (Figure
1). The on-average most prominent ion signals were
found at m/z 66,447, 33,282, and 28,050. These were
assigned as the singly and doubly charged ion signals
of human serum albumin (Mr (avg.): 66,437) and the
singly charged ion signal of apolipoprotein A-I (Mr
(avg): 28,079), respectively.
The mass spectrometric result matched well with
SDS PAGE analysis of the fractionated samples (insert
in Figure 1, lane 2) where protein bands were observed
between 25 and 220 kDa apparent molecular mass.
Comparison of the gel band pattern before (insert in
Figure 1, lane 1) and after fractionation showed that
fractionation removed most of the very high mass
proteins (above 220 kDa) and seemed to enrich for some
proteins in the mass range between 150 kDa and 97 kDa
apparent molecular mass. Note that the strong band at
apparent molecular mass of 55 kDa was identified as
human serum albumin (P02768; Mr (avg.): 66,437) and
the band migrating at 26 kDa apparent mass was
identified as apolipoprotein A-I (P02647; Mr (avg.):
28,079) by in-gel tryptic digest and peptide mass finger-
printing (data not shown).
1704 PECKS ET AL. J Am Soc Mass Spectrom 2010, 21, 1699–1711Protein ion signals in the mass range above m/z
70,000 appeared small in the linear TOF MALDI mass
spectra, presumably due to the rather poor sensitivity of
the multichannel plate detector for high mass ions.
Analysis of the ion signal intensities above m/z 20,000
showed that there were no significant differences be-
tween the spectra of the two sample groups. Hence,
further analysis was focused on the “low mass” range,
i.e., between m/z 4000 and 25,000. As a first measure-
Figure 1. Overview of protein ion signals reco
precipitation from a serum sample of a patient
selected ion signals are labeled). Ion signals wer
as matrix. The insert shows the SDS-PAGE an
sample before (lane 1) and after fractionated p
protein bands were detected below 220 kDa. Th
masses are indicated to the left.
Figure 2. MALDI-TOF mass spectra of serum
preeclampsia patient. (b) Sample from a control
signals are labeled; ferulic acid was used as matrix.ment series, we used the samples after work-up with
the Profiling Kit 100 MB-HIC8 that makes use of
reverse-phase material coated on magnetic beads. After-
wards, on-average 30 intense ion signals were detected
in a reproducible manner (Figure 2).
It is of note that in the linear MALDI-TOF mass
spectra well resolved ion signals were observed in the
mass range below m/z 20,000, whereas in SDS PAGE
analyses of the same samples there were only faintly
by MALDI-TOF-MS analysis after fractionated
preeclampsia (mass range m/z 20,000–220,000;
erved up to ca. 200 kDa. Ferulic acid was used
(10% T, Coomassie blue staining) of a serum
tation (lane 2). After fractionated precipitation
tions of marker proteins with known apparent
les after ClinProt work-up. (a) Sample from a
idual. Mass range m/z 4500–25,000; selected ionrded
with
e obs
alysis
recipi
e locasamp
indiv
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when using 10% gels. This finding may be attributed to
the generally poorer staining properties of smaller
proteins compared with larger proteins and to migra-
tion properties in this mass range so that proteins are
not well focused into sharp bands.
Mass Spectrometric Profiling of Fractionated
Serum Samples from Patients and Control
Individuals using the ClinProt Work-Up Procedure
MALDI linear TOF mass spectra from patient and
control samples in general looked very similar to each
other making a semi-quantitative analysis of the ion
signal intensities feasible. The on-average most abun-
dant ion signals in this mass range were observed atm/z
9390, 9103, and 8886 (Table 2) in all spectra.
To decide whether a distinct ion signal group could
be considered as significantly different in abundance
between the preeclampsia group and the control group,
we performed statistical analyses of the mass spectra
using the ClinProTool software package. According to
the calculated P values, the best differentiating singly
charged ion signals between the two sample groups
were found at m/z 13,715, 13,834, and 13,891 together
with their doubly charged ion signals (Table 2). How-
ever, separation of the two groups based on one of these
ion signal differences alone was not satisfactory as
abundance differences within one group varied too
much (Figure 3). Nevertheless, there was a noticeable
trend of the ion signal abundances around m/z 13,715
being less intense in the preeclampsia group compared
with the control group.
To better distinguish between the two groups and to
more accurately assign a given spectrum to either
belonging to the preeclampsia or the control group, a
multiparametric analysis was performed in which the
normalized ion signal areas (Supplemental Table 1,
which can be found in the electronic version of this
article) within each spectrum were brought into context
to each other.
It turned out that the three most intense singly
charged ion signals and the three best differentiating
Table 2. Statistical data of ion signals selected for multiparamet
Entry m/z Charge PTTA P
1 13891 1 0.019 0.0
2 6945 2 0.12 0.1
3 13834 1 0.0496 0.0
4 6917 2 0.0496 0.0
5 13715 1 0.0383 0.0
6 6858 2 0.037 0.0
7 9390 1 0.885 1
8 9103 1 0.65 0.6
9 8886 1 0.298 0.2
aValues from measurement series MS1 of the preeclampsia group.
bEntries 1–6: best differentiating ion signals according to peak statistic
PWKW  P value from combined Wilcoxon rank-sum test and Kruskal-Walli
cEntries 7–9: most intense ion signals according to average peak areas.singly charged ion signals carried enough information
to form rules by which the relations of the ion signal
intensities enabled accurate sorting of individual spec-
tra, i.e., of individual samples.
Statistical Analysis of Preeclampsia Versus
Control Samples after ClinProt Work-Up
The first measurement series (MS1) that was recorded
after ClinProt work-up was chosen as the training set
for developing the method. The simplest rules that we
selected were to relate the selected ion signals pairwise.
Quotients of the areas of the ion signals at (1) m/z 13,715
and 13,834, (2) m/z 13,891 and 8886, (3) m/z 13,751 and
8886, (4) m/z 13,715 and 9103, as well as (5) m/z 13,834
and 9390 were formed. The resulting ratio distributions
were determined for each of the five pairs (Figure 4)
and showed in fact significant differences (P values
below 0.05) of the value distributions in all five cases.
Consequently, cut-off values (dashed lines in Figure
4) could be determined for all five ratios such that they
were located between the upper 75% quartile of the
group where lower values were obtained (preeclampsia
group) and below the 25% quartile of the other group
(control) where on-average higher values were calcu-
lated for the respective ratios of ion signal areas.
alysis
PAD Peak area/std deva Rankb,c
5 0.0273 70.57/29.16 1
0.00524 15.81/6.27 6
0.00843 121.17/49.68 4
0.0912 38.01/11.77 5
0.00167 280.93/136.72 3
0.00142 77.24/25.47 2
0.174 3109.2/899.53 1
0.265 1660.76/458.3 3
0.345 1803.66/452.78 2
TA  P value from combined paired Student’s t-test and ANOVA test;
Figure 3. Zoom view of protein ion signals in serum samples
after fractionated precipitation by MALDI-TOF-MS; mass range
m/z 13,000–15,000. Spectra from individual samples are visualized
in staggered mode. Numbering of spectra resembles that of
patient samples (cf. Table 1).ric an
WKW
0041
7
114
114
0536
0288
21
03
s (PT
s test; PAD  P value from Anderson-Darling test).
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spectrum the respective cut-off value was reached or
not. When the value of one quotient was higher than the
Figure 4. Box and whisker plots for selected ion intensity differ-
ences from measurement one after ClinProt work-up of serum
samples. (a) Distribution of signal area values of quotient for m/z
13,715 and 13,834. (b) Distribution of signal area values of quotient
for m/z 13,891 and 8886. (c) Distribution of signal area values of
quotient for m/z 13,715 and 8886. (d) Distribution of signal area
values of quotient for m/z 13,715 and 9103. (e) Distribution of
signal area values of quotient for m/z 13,834 and 9390. The boxes
represent the 25th–75th percentiles. The horizontal lines within the
boxes represent the median, the small squares indicate the mean.
The whiskers specify the 5th and 95th percentiles, and the crosses
indicate the 1st and 99th percentiles. Dashed lines mark selected
cut-off values. PE: preeclampsia; CN: control. P values are given.respective cut-off, a score of “1” was given to thisrespective sample. In the contrary case, the score for this
sample was set to “0.” This check was carried out for
each of the five ion signal ratios independently. Hence,
each spectrum, i.e., each sample, could ultimately reach
a cumulative score between “0” and “5.” Subsequently,
it was determined that a cumulative score above “2”
was sorting the respective spectrum (sample) into the
preeclampsia group. Applying these grouping rules for
the values of the first measurement series (M1) enabled
a clear-cut separation of all preeclampsia samples into
the preeclampsia group and all control samples into the
control group (Table 3). Ultimately, the scoring system
resulted in a sensitivity of 1.00, a specificity of 1.00, a
false positive rate of 0.00, a false negative rate of 0.00, a
positive predictive value of 1.00, and a negative predic-
tive value of 1.00 for the first measurement series (MS1).
Now we applied the very same rules to the second
measurement series (MS2) using the normalized ion
signal areas from this measurement (Supplemental Ta-
ble 2). This measurement series was recorded a few
days later than the first measurement series (MS1)
without fresh fractionation work-up. Hence, this mea-
surement series can be regarded as a first test case. A
decrease in the accuracy of the separation procedure
was expected. However, the decrease in specificity to
0.62 and a false positive rate of 0.38 was regarded as
being too large to qualify our approach as a satisfactory
procedure. To determine whether the poor statistical
significance obtained with the second measurement
series (MS2) was due to non-satisfactory separation
rules or to sample deterioration during storage after
work-up, we performed a new fractionation experiment
with freshly thawed aliquots from the clinical samples,
following the exact same work-up protocol as before.
A third measurement series (MS3; Supplemental
Table 3) was recorded and analyzed again directly after
work-up. The over-all analysis results showed that now
a sensitivity of 0.91, a specificity of 0.85, a false positive
rate of 0.15, a false negative rate of 0.09, a positive
predictive value of 0.83, and a negative predictive value
of 0.92 was reached with this measurement series. To
confirm that after work-up the samples deteriorated
over time, a fourth measurement series (MS4; Supple-
mental Table 4) was recorded again a few days later
with the material from the second fractionation. As
expected, the specificity dropped to 0.69 yielding in a
false positive rate of 0.31.
Verification of the Differentiation Results by Using
Fractionated Precipitation as Work-Up
Next, we checked whether the ion signal differences
recorded in the measurement series MS1 to MS4 were
merely a result of the work-up procedure using
reversed-phase material coated magnetic beads. To do
this, we were working-up the starting material, i.e.,
frozen patient serum samples, by applying a fraction-
ated precipitation procedure. Fraction II from this pro-
wer
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mass spectrometric analysis (measurement series MS5).
Obviously, as the protein mixtures in these samples were
different from those obtained with the ClinProt work-up
protocol, the spectra of measurement series MS5 looked
slightly different than those obtained e.g., from measure-
ment seriesMS1. Yet, the spectra that were obtained for all
24 samples from this work-up again showed that the most
intense ion signals were the same as those obtained after
ClinProt work-up. The only significant difference between
the spectra was the relative ion signal intensities and the
respective ion signal areas (Supplemental Table 5) so that
different values resulted for their quotients.
Nevertheless, it was again possible to assign cut-off
values using the same procedure as described above
(Figure 5) and only in the case of the ratio of the pair
with m/z 13,834 and 9390, the chosen cut-off value was
above the lower 25% quartile of the control group
(Scheme E in Figure 5).
Despite this fact, we decided to not change the rules
and scored the spectra, i.e., samples, exactly as described
above using the cut-off values from measurement series
MS5. As a result, we obtained comparably cumulative
scores and sorting of each sample resulted in a sensitivity
of 0.91, a specificity of 0.92, a false positive rate of 0.08, a
false negative rate of 0.09, a positive predictive value of
0.91, and a negative predictive value of 0.92 (Table 3),
which was considered quite satisfactory.
SDS Polyacrylamide Gel Analysis of Preeclampsia
and Control Samples
As two completely independent protein fractionation
procedures enabled the differentiation of the preeclampsia
group from the control group by analyzing the linear
MALDI TOF mass spectra with high accuracy, we
analyzed selected patient and control samples, i.e.,
fraction II after fractionated precipitation, also by SDS
PAGE. Special interest was given to the mass range
below 20 kDa apparent mass, and therefore a 12% gel
was used. Protein bands were visualized by colloidal
Coomassie brilliant blue staining (Figure 6).
About six protein bands were visible in the mass
Table 3. Statistical significance of mass spectrometric profiling r
Measurement
True
positive
False
positive
True
negative
False
negative
MS1a 11 0 13 0
MS2a 10 5 8 1
MS3b 10 2 11 1
MS4b,c 10 4 9 0
MS5d 10 1 12 1
aFirst ClinProt work-up.
bSecond ClinProt work-up.
cspectra from patients 12, 14, 21, and 23 were of poor quality; samples
dFractionated precipitation work-up.range between 20 and 6.5 kDa in both, the preeclampsiasamples (patients 5 and 7) and the control individuals
(15 and 23) before (lanes 1) and after (lanes 2) fraction-
ated precipitation. The four intense protein bands were
subjected to mass spectrometric identifications after
in-gel digestion with trypsin. From these analyses, it was
found that the band migrating at 20 kDa apparent mass
contained the retinol binding protein 4 (P02753; Mr (avg.):
20,943) as the major compound. The band migrating
below was determined to contain apolipoprotein A-II
(P02652; Mr (avg.): 17,160 for the homodimer). The band
migrating just above the 14 kDa marker band contained
transthyretin (P02766; Mr (avg.): 13,761) and the band at
6.5 kDa apparent mass contained apolipoprotein C-III
(P02656; Mr (avg.): 8765). All identifications were obtained
with good identification scores (data not shown), indicat-
ing that the identified proteins were in fact the major
compounds in their respective bands.
Densitometric analysis of the protein bands of the
SDS PAGE analysis showed that the intensities of
the bands that contained transthyretin were lower in the
preeclampsia samples with respect to those of the con-
trol samples. For normalization, the band intensities
were set into relation to the intensities of the apoli-
poprotein A-I bands of the very same sample (band
migrating at 26 kDa apparent mass, cf. Figure 1). Such
normalized transthyretin band volumes were deter-
mined using the serum samples before fractionation
(lanes 1 in Figure 6) and yielded in values of 0.057 (patient
5) and 0.089 (patient 7) for the preeclampsia group. The
respective values of the samples from the control group
were 0.137 (control 23) and 0.118 (control 15), respectively.
Hence, from the SDS PAGE and the mass spectro-
metric results it was tempting to speculate that the
protein ion signals at m/z around 13,715 belonged to
transthyretin. Consequently, we postulated that transt-
hyretin levels in preeclampsia samples were lower than
those in the control samples.
Quantitation of Transthyretin Levels in Serum
Samples
To substantiate the hypothesis that transthyretin levels
in sera of patients suffering from preeclampsia were
s
Sensitivity Specificity
False
pos.
rate
False
neg.
rate
Pos.
pred.
value
Neg.
pred.
value
1.00 1.00 0.00 0.00 1.00 1.00
0.91 0.62 0.38 0.09 0.67 0.89
0.91 0.85 0.15 0.09 0.83 0.92
0.91 0.69 0.31 0.09 0.71 0.90
0.91 0.92 0.08 0.09 0.91 0.92
e set to “false positive.”esultlower than those in control sera, we subjected freshly
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results from this assay showed that the mean concen-
Figure 5. Box and whisker plots for selected ion intensity differ-
ences from measurement five after fractionated precipitation
work-up of serum samples. (a) Distribution of signal area values
of quotient for m/z 13,715 and 13,834. (b) Distribution of signal
area values of quotient for m/z 13,891 and 8886. (c) Distribution of
signal area values of quotient for m/z 13,715 and 8886. (d)
Distribution of signal area values of quotient for m/z 13,715 and
9103. (e) Distribution of signal area values of quotient for m/z
13,834 and 9390. The boxes represent the 25th–75th percentiles.
The horizontal lines within the boxes represent the median, the
small squares indicate the mean. The whiskers specify the 5th and
95th percentiles, and the crosses indicate the 1st and 99th percen-
tiles. Dashed lines mark selected cut-off values. PE: preeclampsia;
CN: control. P values are given.tration of transthyretin in the preeclampsia group waslower (0.16 mg/mL; range: 0.13 to 0.20; SD: 0.03; n 11)
than that in the control group (0.19 mg/mL; range: 0.14
to 0.22; SD: 0.02; n  13). It should be noted that the
Student’s t-test for two populations showed statistical
significance in the difference between the two groups
(P  0.03). The on-average lower transthyretin concen-
tration in the preeclampsia group stands in agreement
with the results reported above.
Statistical Power Analysis
Having obtained the data of measurement 1 (MS1), we
calculated the minimal required sample size needed for
further analyses. By using the rule sets as described
above, we calculated a required sample size of n  10
patients for each group. This result was achieved also
with measurement series MS5 independently with only
one exception. Here, ratio “5” suggested a sample size
of n  18, mirroring the poorer differentiation potential
as already expected due to the less clear-cut line of
separation (see above). However, as in each measure-
ment series a total number of five independent ratios
were determined in parallel, the exceptionally higher
sample size prediction by one ratio determination was
overruled by the accompanying four other ratio consid-
erations. They suggested a smaller sample size (n 10).
In summary, we considered the number of patients
included in the here described study (11 individuals in
the PE group and 13 individuals in the control group) as
being sufficient for supporting the statements that re-
sulted from the investigations described here.
Discussion
During the last decade, preeclampsia has attracted
increasing interest among researchers, predominantly
because of two main reasons. First, as an acute disorder,
preeclampsia is a major cause of maternal and neonatal
morbidity and mortality [41], and early identification of
the risk of developing the condition would provide a
better surveillance during pregnancy and, therefore,
improve outcome. Second, as a chronic risk factor, it has
become apparent that developing preeclampsia has
implications also in later life, i.e., women with pre-
eclampsia during pregnancy are at increased risk of
Figure 6. SDS-PAGE analysis (12% T, mass range: 6–20 kDa) of
serum proteins before and after fractionated precipitation (frac-
tions II) from preeclampsia and control samples. Protein bands
(Coomassie blue staining) from samples of patients with pre-
eclampsia (patients 5 and 7) and from control individuals (15 and
23) before (lanes 1) and after fractionated precipitation (lanes 2)
are shown. Mass spectrometrically identified proteins in the bands
are indicated at the left. The locations of marker proteins with
known apparent masses are given at the right.
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their life [42]. Still, the prediction of women at
increased risk for developing preeclampsia remains
problematic. But only with the help of a reliable
predicting marker—or a predicting signature that con-
sists of several markers—it would become meaningful
to recruit pregnant women into trials of potential ther-
apeutic agents or treatment with already established
early interventions, such as aspirin. The latter has been
shown to reduce the recurrence risk of preeclampsia
and perinatal death [43].
Few efforts have been made to adopt proteomic
methods into the research of pregnancy-related hyper-
tensive disorders. Mass spectrometry was primarily
applied to identify proteins of interest after separation
of serum and/or plasma proteins by 2D gel electro-
phoresis. Using such an approach serum clusterin con-
centrations were found to be significantly increased in
preeclampsia [44]. Clusterin is a 70 kDa protein associ-
ated with high-density lipoproteins (HDL) in human
plasma. It also acts as a control mechanism of the
complement cascade as it is present in the S protein-
containing soluble variant of the C5b-9 complex [45, 46].
Likewise, 36 proteins were identified by liquid chroma-
tography tandem mass spectrometry (LC-MS/MS)
upon 2-D fluorescence difference gel electrophoresis
(DIGE) during the analysis of protein abundance differ-
ences in plasma samples from women with preeclamp-
sia at 20 wk of gestation and preceding the onset of
symptoms [47]. Interestingly, 18 of these proteins are
associated with HDL particles [48]. The authors sug-
gested these so-called “cargo proteins” to modify the
anti-inflammatory properties of HDL and, thus, might
be linked to the relationship between preeclampsia and
later coronary artery disease. Interestingly, a recent
proteome study of plasma proteins of a “late-onset
subgroup” of preeclampsia revealed that transthyretin
levels, besides other factors, were elevated compared
with those from healthy pregnant controls [49].
In the study described here, we observed a group of
protein ion signals that can be regarded as a signature
for preeclampsia with the most prominent group of ion
signals around m/z 13,715. SDS PAGE analysis and
peptide mass fingerprinting suggested that the mentioned
ion signals belonged to transthyretin. Nephelometric anal-
yses showed consistently lower transthyretin concentra-
tions in samples from preeclampsia patients with respect
to the control group. It should be noted that the transt-
hyretin concentrations of all samples were below the
reference value for serum, which is expected to be the
case during pregnancy due to plasma volume expan-
sion [50]. To the best of our knowledge, this is the first
report of a decrease in transthyretin concentration in
serum of the “subgroup of severe early-onset pre-
eclampsia” before 34 gestational week with respect to
transthyretin levels of individuals with uneventful
pregnancies.Transthyretin is a typical so-called “negative acute
phase protein.” After trauma, surgery, inflammation,
or malnutrition, transthyretin transcription is down-
regulated in the liver and protein levels in the blood
are markedly decreased [51]. Transthyretin acts as a
transport molecule for thyroid hormones. Thus, it
might ensure the uniform delivery of thyroid hormones
throughout all tissues of an organism. Furthermore, it
binds the retinol-binding protein, possibly to prevent
loss of retinol through glomerular filtration in the
kidneys [52]. Most interestingly, transthyretin is not
only synthesized by the liver but is also secreted by
placental trophoblasts where it binds extracellular T4,
which in turn result in an increased internalization of
the transthyretin-T4 complex. It has been suggested
that transthyretin plays an important role in the
transfer of maternal thyroid hormone to the fetal
circulation, which could have important implications
for fetal development [53].
In our experiments, it turned out that just one marker
protein ion signal was not sufficient to differentiate an
individual preeclampsia sample from a control sample.
By contrast, so-called “multifactorial signatures” are
believed to be adequate for distinguishing two poly-
genic phenotypes to be differentiated [54–58]. Although
we did not identify the underlying proteins of the other
ion signals in the vicinity of the ion signal at m/z 13,715
(m/z 13,891 and 13,834), it seemed likely that these
originated from covalent transthyretin modifications
[59]. Likewise, the nature of the many other protein ion
signals in our mass spectra has not yet been determined.
Our SDS PAGE analysis results indicated that apolipopro-
teins should perhaps be of interest in this context, putting
HDL components again into the focus of research, consis-
tent with above discussed reports [48].
In a comparable screening approach, we recently
reported on the development of a proteomic signature
applying a mass spectrometry-based method for the
HELLP syndrome, where we subjected plasma proteins
to MALDI-TOF mass spectrometry. Using an instru-
ment equipped with a cryodetector, we demonstrated
that this method enabled the simultaneous recording of
significant differences in protein ion intensities between
the control group and HELLP patients without sample
fractionation, even for larger protein ions above 40 kDa
[17]. Further analysis identified serum amyloid A1
(SAA1) to show the most striking differences in abun-
dance from all constituents of the signature. SAA consists
of a family of proteins which is functionally up-regulated,
presumably due to liver involvement during the HELLP
syndrome [3]. Again, this one factor was not considered
enough to sort the samples to either belong to the
disease group or to the control group, but the signature
as a whole yielded satisfactory results.
Altogether, our findings support the theory of pre-
eclampsia being a heterogeneous disorder [21, 22, 60]
that might be sub-classified according to different pro-
tein concentrations in maternal blood. As is the case for
marker proteins, the success of a “multifactorial signa-
1710 PECKS ET AL. J Am Soc Mass Spectrom 2010, 21, 1699–1711ture” in general is depending on (1) the roles that some
of the proteins from the defined signature play in
pathogenesis and, perhaps, equally important, (2) the
“ease” with which such signatures can be screened in
large(r) cohorts of patients. The “preeclampsia signa-
ture” described by us relies on differential protein
expression in a limited number of patients and, there-
fore, can be regarded to be in just a preliminary state. It
is of note that the clarity of differentiation between
preeclampsia and control samples has improved with
fractionating serum proteins before performing mass
spectrometric analyses. This leaves room for differenti-
ating future samples with more heterogeneities as they
are expected with further patient samples.
Also of importance for the analysis of clinical
material is to maintain minimal sample manipulation
before analysis. Our described procedure fulfills this
prerequisite as demonstrated here in an advanced
clinical research environment. Although present mass
spectrometry-based methods are not yet ready for im-
mediate clinical use as routine diagnostic tools but
require close collaboration of clinicians with research-
ers, it can be envisaged that simple, fast, robust, porta-
ble, and cost-effective clinical diagnosis systems could
become available soon, which are compatible with
usage in the case room. Following this direction, further
studies have been initiated by us with the goal to
classify subtypes of preeclampsia for a better under-
standing of the disease. Ultimately, we intend to eval-
uate the clinical usefulness of the here developed
MALDI-TOF MS-based screening approach in a larger
multicentric study, and compare efficacy of this method
with those of already discussed serum biomarkers.
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